Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partners
Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat.com reports. Leerink Partners currently has $6.00 price target on the stock, up from their prior price target of $4.00. Several other brokerages have also weighed in […]
Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat.com reports. Leerink Partners currently has $6.00 price target on the stock, up from their prior price target of $4.00. Several other brokerages have also weighed in […]
